

## Special Issue

# Surgical Management of Gastrointestinal Cancers

### Message from the Guest Editor

Gastrointestinal (GI) cancers drive morbidity and mortality throughout the world. Surgical resection remains the primary treatment modality and only opportunity for long-term survival in most patients. Furthermore, developments in immunotherapy and targeted therapy have improved disease control in patients with metastatic disease, expanding the therapeutic window for potentially curative surgical intervention. Finally, minimally invasive surgical techniques and technological adjuncts have improved patient outcomes and are expected to significantly enhance the management of GI cancers moving forward. In this Special Issue, we focus on the surgical management of GI cancers, including esophageal, gastric, small intestine, appendiceal, colorectal, liver, pancreatic, and biliary cancers. In addition to discussions on the timing and sequence of surgical intervention, comments are encouraged on the expanding role of molecular profiling throughout the surgical decision-making process. This Special Issue aims to collect novel insights and future perspectives regarding the current surgical management of GI cancers.

### Guest Editor

Dr. Brock Hewitt

NYU Grossman School of Medicine, NYU Langone Health, New York, NY 10016, USA

### Deadline for manuscript submissions

closed (1 December 2023)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/169202](https://mdpi.com/si/169202)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)